MedTrace Logo

Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection

NCT05718609 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 855

Last updated 2023-05-15

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of 14-day quadruple therapy based on fecal molecular antimicrobial susceptibility tests for the first-line eradication of H. pylori infection, thus, providing more evidence to inform the value of fecal antimicrobial susceptibility tests in the first-line treatment of H. pylori infection.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Rabeprazole

proton-pump inhibitor (PPI)

DRUG

Colloidal Bismuth Pectin Granules

Gastric mucosal protective drug with anti-H. pylori effect

DRUG

Amoxicillin

Antibiotic for H. pylori eradication

DRUG

Furazolidone

Antibiotic for H. pylori eradication

DRUG

Clarithromycin

Antibiotic for H. pylori eradication

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Qin Du, Master · Second Affiliated Hospital of Zhejiang University, School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-03-01
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05718609 on ClinicalTrials.gov